|
Carcinoma
|
0.190 |
AlteredExpression
|
group |
BEFREE |
We included a total of 108 cases comprising 10 benign and 6 malignant sweat gland tumors, and KIT expression was immunohistochemically detected (positive rate): 10 syringomas (0%), 8 poromas (25%), 20 mixed tumors (40%), 21 spiradenomas (43%), 1 cylindroma (0%), 5 hidradenomas (40%), 7 syringocystadenoma papilliferum cases (0%), 1 papillary hidradenoma (100%), 2 tubulopapillary hidradenomas (50%), 8 hidrocystomas (29%), 2 adenoid cystic carcinomas (100%), 5 porocarcinomas (20%), 6 apocrine carcinomas (33%), 10 extramammary Paget diseases (30%), 1 spiradenocarcinoma (100%), and 1 syringocystadenocarcinoma papilliferum (0%).
|
25634571 |
2015 |
|
Carcinoma
|
0.190 |
Biomarker
|
group |
BEFREE |
Several therapy leads were identified, including high levels of HER2 and androgen receptors in salivary duct carcinomas, C-KIT in myoepithelial carcinomas and EGFR in mucoepidermoid carcinomas.
|
23933559 |
2013 |
|
Carcinoma
|
0.190 |
Biomarker
|
group |
BEFREE |
c-KIT expression was scored by immunohistochemistry (IHC) as positive or negative in 139 formalin-fixed paraffin-embedded (FFPE) cases of vulvar carcinomas arrayed in a tissue microarray (TMA) using the DAKO A4502 rabbit polyclonal c-KIT antibody (diluted 1:100). c-KIT mRNA was evaluated by qRT-PCR in 34 frozen samples from AC Camargo Hospital Biobank (17 tumoral and 17 non-tumoral samples) using TaqMan probes-Applied Biosystems [Hs00174029_m1].
|
22839358 |
2012 |
|
Carcinoma
|
0.190 |
GeneticVariation
|
group |
BEFREE |
We performed immunohistochemistry (epidermal growth factor receptor (EGFR), HER2, and CD117), EGFR and ERBB2 fluorescence in situ hybridization (FISH), and multiplexed SNaPshot® genotyping (testing for recurrent mutations in 15 cancer genes including BRAF, EGFR, KRAS, PIK3CA, and TP53) on primary tumors and corresponding metastases of 14 metastasizing adnexal carcinomas (three apocrine, six eccrine, two hidradenocarcinomas, two porocarcinomas, and one aggressive digital papillary adenocarcinoma).
|
21423156 |
2011 |
|
Carcinoma
|
0.190 |
Biomarker
|
group |
BEFREE |
The remaining 2 carcinomas previously reported as malignant RO owing to cytological atypia and lymph node metastasis showed immunoprofile of RCC(-)/CD117(+) and absence of numeric changes for chromosomes 7, 17, and Y or loss of loci 3p25 or 3p14.
|
20861792 |
2011 |
|
Carcinoma
|
0.190 |
AlteredExpression
|
group |
BEFREE |
RNA in situ hybridization showed KIT mRNA expression in most glioblastomas both in tumour vessel endothelial cells and in perinecrotic palisading glioblastoma cells, whereas little KIT mRNA was found in the endothelial cells of colon or pancreatic carcinomas.
|
17294421 |
2007 |
|
Carcinoma
|
0.190 |
AlteredExpression
|
group |
BEFREE |
KIT expression was detected in 12% of carcinomas: low expression in 10% and high expression in 2% of cases.
|
15583695 |
2004 |
|
Carcinoma
|
0.190 |
AlteredExpression
|
group |
BEFREE |
We analyzed the immunohistochemical expression for KIT in 256 conventional renal cell carcinomas (RCCs), 29 chromophobe RCCs, 25 papillary RCCs, 6 collecting duct RCCs, 6 unclassified RCCs, 7 renal oncocytomas, 20 urothelial carcinomas, 7 nephroblastomas, and 23 angiomyolipomas.
|
15198361 |
2004 |
|
Carcinoma
|
0.190 |
AlteredExpression
|
group |
BEFREE |
To study the role of c-kit in salivary gland carcinomas, we analyzed the c-kit protein expression in 79 carcinomas of major and minor salivary glands by immunohistochemistry.
|
10799746 |
2000 |
|
Carcinoma
|
0.190 |
Biomarker
|
group |
HPO |
|
|
|